Disrupting this pathwayeither by severing kidney sensory nerves, selectively deleting the angiotensin II type 1a receptor (AT1a) in the subfornical organ (SFO), or using optogenetics to silence the kidney-SFO or SFO-paraventricular nucleus (PVN) connectionsreduces sympathetic output, which in turn diminishes structural damage and functional impairment in the kidneys and heart in these models of CKD and heart failure (Cao et al., 2023)
Deferoxamine has demonstrated efficacy in preclinical models of ARDS, where it mitigates iron-driven oxidative damage and inflammation (100)
Aoyama K, Suh SW, Hamby AM, et al
Cerebrolysin has been proven to have nerve growth action causing peripheral and central neuronal stimulation
10.1124/jpet.107.134882 143 Ros-SilvaM.Santos- lvarezR.TrujilloX.Crdenas-MaraR
Understanding these research-backed protocols helps inform safe, effective therapeutic approaches under medical supervision